ALKERMES | ALKS - Ingresos Por Ventas





Ventas Cambio Fecha
AbbVie USD 16.99B 1.99B 2026-06
Acadia Pharmaceuticals USD 307.96M 39.9M 2026-06
ALKERMES USD 496.01M 103.1M 2026-06
Amgen USD 10.1B 1.48B 2026-06
Biogen USD 2.74B 490M 2026-06
BioMarin Pharmaceutical USD 990M 224M 2026-06
Bristol-Myers Squibb USD 12.97B 1.48B 2026-06
Coherus Biosciences USD 12.75M 1.18M 2025-12
Eli Lilly USD 22.97B 3.17B 2026-06
Gilead Sciences USD 7.8B 800M 2026-06
Heron Therapeutics USD 40.59M 2.38M 2025-12
Ionis Pharmaceuticals USD 268M 22M 2026-06
J&J USD 25.31B 1.21B 2026-06
Merck USD 16.6B 310M 2026-06
Minerva Neurosciences USD 0 0 2024-09
Nektar Therapeutics USD 10.86M 10.95M 2026-03
Neurocrine Biosciences USD 959M 148M 2026-06
Otsuka Holdings JPY 702.05B 71.71B 2026-06
Pfizer USD 15.03B 530M 2026-06
Regeneron Pharmaceuticals USD 4.29B 690M 2026-06
Vertex Pharmaceuticals USD 3.33B 340M 2026-06